Supplementary Table S2. Association between PD-L1 expression and systemic inflammatory markers

Variable	NLR			PLR			MLR		
	Median (IQR)	p-value	p-trend	Median (IQR)	p-value	p-trend	Median (IQR)	p-value	p-trend
CPS		.177	.607		.102	.377		.116	.423
<1	3.00 (2.23–4.29)			151.11 (132.05–222.48)			0.29 (0.20–0.36)		
1–5	2.58 (1.99–5.04)			161.56 (124.28–230.93)			0.29 (0.22–0.48)		
>5–10	2.48 (1.89–3.03)			132.71 (95.24–182.51)			0.23 (0.17–0.32)		
>10	3.72 (1.79–5.01)			165.20 (112.93–243.57)			0.28 (0.20–0.37)		
IC expression (%)		.907	.861		.539	.499		.578	.465
<1	2.70 (2.10–4.28)			155.09 (128.80–208.55)			0.28 (0.21–0.37)		
1–5	2.55 (1.99–4.38)			164.81 (120.05–227.97)			0.28 (0.21–0.45)		
>5	3.03 (1.74–4.03)			150.56 (102.39–186.05)			0.25 (0.19–0.36)		
TC expression (%)		.957	.826		.671	.545		.672	.891
<1	2.77 (2.05–4.30)			156.23 (128.80–230.16)			0.28 (0.19–0.40)		
1–5	2.67 (1.99–4.32)			147.71 (110.83–211.04)			0.26 (0.21–0.40)		
>5	3.11 (1.78–3.88)			158.08 (133.54–175.66)			0.24 (0.18–0.33)		

Values are presented as median (IQR). Group comparisons were performed using nonparametric tests as appropriate for skewed distributions, and p for trend was calculated across ordered PD-L1 categories when applicable.

PD-L1, programmed cell death ligand 1; NLR, neutrophil-to-lymphocyte ratio; IQR, interquartile range; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; CPS, combined positive score; IC, immune-cell PD-L1; TC, tumor-cell PD-L1.